NCT06038526 2026-02-19
Evaluation of Canakinumab in High-Risk Former-Smokers
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT05641831 2026-01-02
Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT04789681 2025-12-26
Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04239157 2025-11-18
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05467800 2025-11-18
Study of Canakinumab in Patients With Myelofibrosis
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
NCT04028245 2025-08-07
SPARC-1
Columbia University
Phase EARLY_PHASE1 Active not recruiting
NCT04905316 2025-06-17
CHORUS
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04581343 2025-05-04
PanCAN-SR1
Pancreatic Cancer Action Network
Phase 1 Completed
NCT05984602 2025-04-15
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
NYU Langone Health
Phase 1 Recruiting
NCT05725343 2023-02-13
CANAL
Mario Negri Institute for Pharmacological Research
Phase 3 Terminated